Two events likely in the rearview mirror in March are the REACH2HD results, and the advance within the Michael J. Fox milestone based 2011 Pipeline drug therapeutics program that PBT434 is part of for Parkinson's ($4 Billion market). The initial grant in the annual report was meant through calendar year 2013, our grant work is completed, and they bumped the first-in-human testing target from 2015 to by the end of 2014 - which sets a more aggressive deadline at least by one day ;-) I would guess a follow-on grant would be funding PBT434 into a Phase I trial.
So could be right or wrong on the dead money.
coiled spring?, page-35
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $1.937K | 645.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 77 | 96988980 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 655773 | 2 |
View Market Depth
| Last trade - 10.00am 15/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |